Sublingual Immunotherapy Effective in Cat-allergic Patients

Pam Harrison

December 12, 2014

Allergens modified by carbamylation so that they can be absorbed by the oral mucosa and given as sublingual immunotherapy have once again been found to be effective in patients with rhinoconjunctivitis and allergic asthma caused by cat allergies, a cross-sectional survey suggests.

"Monomeric allergoid sublingual tablets show clinical advantages in a practice environment and under real-life conditions," according to Bettina Hauswald, MD, from Uniklinikum Dresden in Germany, and colleagues.

"We found that a sublingual monomeric tablet therapy is safe, well tolerated, and significantly reduces rhinitis symptoms in cat-allergic patients," they report.

The study was presented at the World Allergy Organization International Scientific Conference and Congress of the Brazilian Association of Allergy and Immunology in Rio de Janeiro.

Sublingual monotherapy with carbamylated monomeric allergoid tablets has been used to treat a variety of allergies over the past number of years, including grass-, pollen-, and dust mite-induced allergic rhinoconjunctivitis, and allergic ocular symptoms in patients with allergic rhinitis.

In the current study, patients with cat allergies in the form of rhinoconjunctivitis or asthma were prescribed monomeric allergoid sublingual tablets. The tablets were initially given in titrated doses, but were tapered for maintenance therapy.

A questionnaire, completed by 70 patients, was used to determine details of symptomatic improvement, the use of medications for symptomatic relief, and adverse effects.

Table. Resolution of Symptoms After Sublingual Therapy

Year of Therapy Rhinitis, % Conjunctivitis, % Cat-allergic Asthma, %
First 29 37 35
Second 53 55 58
Third 73 73 70


Between baseline and the survey, the use of asthma medication dropped from a mean of 1.33 to a mean of 0.68 medications (P ≤ .05). Similarly, the use of antiallergy medications dropped from a mean of 1.01 at baseline to a mean of 0.45 (P ≤ .001).

"No events of death, no anaphylactic reactions, no serious adverse events, and no systemic adverse reactions occurred," the researchers point out, "and only seven local adverse reactions were reported in seven patients."

Improvement in quality of life, patient satisfaction, and trust in the therapy were also "remarkably enhanced," they add.

There was no commercial funding for this study. The authors have disclosed no relevant financial relationships.

World Allergy Organization International Scientific Conference (WISC) and Congress of the Brazilian Association of Allergy and Immunology: Abstract 2141. Presented December 8, 2014


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.